Articles from IQVIA

IQVIA Laboratories, a leading global drug discovery and development laboratory services organization, announces the launch of Site Lab Navigator, an advanced suite of solutions that automates and streamlines lab workflows for clinical trial sponsors and investigator sites.

IQVIA (NYSEIQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences and healthcare industries, today announced that IQVIA AI Assistant has been awarded a 2024 PM360 Innovation Award in the Artificial Intelligence category.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the TD Cowen Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. ET.

IQVIA (NYSEIQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has published its 2024 Sustainability Report. The report details IQVIA’s sustainability achievements consistent with its mission to accelerate innovation for a healthier world.

IQVIA (NYSEIQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune® World’s Most Admired Companies™ list. This is the fourth year in a row IQVIA has earned first place in the Health Care: Pharmacy and Other Services category, and the eighth consecutive year it has appeared on the list. Notably, IQVIA earned first place in its category on four key attributes — innovation, global competitiveness, people management and use of corporate assets.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV) will announce its fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.

IQVIA (NYSEIQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, today announced a strategic collaboration with NVIDIA to help realize the potential of AI in healthcare and life sciences.

Despite a drop in venture funding for digital health companies over the last two-and-a-half years, digital health products and solutions are expanding in scope and function to aid patient diagnosis, treatment, and monitoring. More solutions are now focused on specific diseases, and their commercial appeal has grown as developers build solutions that bring value back to providers, are more easily integrated with health systems, and embrace innovation such as AI to personalize care and reduce provider workload. Product types have also expanded, with health assessment tools such as digital diagnostics, sensor-based digital measures, and remote patient monitoring solutions joining digital therapeutics and consumer health apps to offer value for personal health and clinical care. These findings are based on a new report from the IQVIA Institute for Human Data Science: Digital Health Trends 2024: Implications for Research and Patient Care.

IQVIA (NYSEIQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today introduces IQVIA AI Assistant, a generative AI technology that enables a step-change enhancement in how life science customers receive timely and powerful insights.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Frost & Sullivan, a leading independent research and consulting firm, has awarded IQVIA with the 2024 Global Customer Value Leadership Award for excellence in the global artificial intelligence (AI) quality and regulatory solutions space for the healthcare industry.

IQVIA™ (NYSEIQV) today announces that a leading, independent research firm, Everest Group, has recognized IQVIA as a Leader in its Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024 survey, which measures both market impact and delivery effectiveness.

IQVIA™ (NYSEIQV), a leading global provider of AI-powered analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the IQVIA SmartSolve Enterprise Quality Management System (eQMS) platform has been selected as the winner of the “Best Use of Artificial Intelligence in Healthcare" award in the 8th Annual MedTech Breakthrough Awards.

IQVIA (NYSEIQV) today announced the launch of One Home for Sites™, a new technology platform that acts as a single sign-on and a single dashboard for the key systems and tasks a clinical research site needs to perform across all of the clinical trials it is conducting.

As cancer incidence continues to rise, it’s being met by wider use of innovative therapies and a robust pipeline of new drugs, according to a new report from the IQVIA Institute for Human Data Science titled, “Global Oncology Trends 2024: Outlook to 2028.”

Overall spending in the U.S. market for medicines grew by 2.5% and reached $435Bn in 2023. Excluding the contribution from COVID-19 vaccines and therapeutics, spending grew at 9.9%, according to a new report from the IQVIATM Institute for Human Data Science, The Use of Medicines in the U.S. 2024: Usage and Spending Trends and Outlook to 2028.

IQVIA (NYSEIQV) today announced that Wendy Stewart, president of Clinical Operations at IQVIA, and Susan Barnes, senior director of IQVIA Biotech Strategic Operations, have been honored with the Healthcare Businesswoman's Association Luminary and Rising Star Awards, respectively.

IQVIA (NYSEIQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce NYSE:CRMNYSECRM)

IQVIA™ (NYSEIQV), has published its 2023 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients.

Global biopharma R&D productivity rebounded in 2023 with higher composite success rates enabled by industry-wide and regulator adoption of data and technology driven innovation, including novel trial design, optimized biomarker use, and digital and decentralized trial methodologies. This rebound occurred while clinical trial starts and funding returned to pre-pandemic levels, according to the new report, “Global Trends in R&D 2024: Activity, Productivity, and Enablers,” released by the IQVIA Institute for Human Data Science.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to the Fortune® World's Most Admired Companies™ list for the seventh consecutive year.

Global spending and demand for medicines will increase over the next five years to approximately $2.3 trillion by 2028 as more patients get access to new and better medicines, according to a new report from the IQVIA Institute for Human Data Science titled, “The Global Use of Medicines 2024 – Outlook through 2028.”

IQVIA™ (NYSEIQV), a leading global provider of data, analytics, technology solutions and services to the life sciences industry, today announced that IQVIA Digital Enablement has been named a PM360 Trailblazer 2023 Company of the Year in the Supplier/Vendor category.

IQVIA Holdings Inc. (NYSEIQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer” or “Borrower”), intends to raise $500,000,000 through an offering of senior secured notes due 2029 (the “Notes”).

IQVIA™ (NYSEIQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, announced that Dr. Christina Mack, chief scientific officer, has been named to the 2023 PharmaVoice 100 list.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2023.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announced that Sanofi will use the IQVIA OCE platform in select countries across Africa and the Middle East.

IQVIA, (NYSEIQV), a leading global provider of advanced analytics, technology solutions, and clinical research services, and The Coalition for Epidemic Preparedness Innovations (CEPI) today announced a strategic collaboration to advance the 100 Days Mission.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV) will announce its third-quarter 2023 financial results before the market opens on Wednesday, November 1, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.

Patient organizations play a vital role in the U.S. healthcare system, according to a new report from the IQVIA Institute for Human Data Science, Supporting Patients through Research Collaboration: Interactions Between Patient Organizations and Life Sciences Companies. Over the past five years, patient organizations have contributed $22.2 billion in grants to support patient services, research, and access to care.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a strategic collaboration with argenx to advance treatment to patients with rare autoimmune diseases through innovative and integrated technology-enabled pharmacovigilance (PV) safety services and solutions.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit.

IQVIA™ (NYSEIQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, has been named a Leader in the IDC Marketscape Worldwide Life Science R&D Pharmacovigilance Solutions 2022 Vendor Assessment.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV), announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Morgan Stanley Annual Global Healthcare Conference in New York City on Tuesday, September 12, 2023 at 11:30 a.m. ET.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, today announced that it has been recognized along with the National Basketball Association and partners at Harvard, Columbia and BioReference Laboratories for its work in supporting the league with the 2020 NBA Bubble. The Bubble was a closed-campus occupational health program implemented to ensure the smooth operation of the professional basketball league during the COVID-19 pandemic.

IQVIA™ (NYSEIQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, was recognized as the highest scoring provider in the ‘Leader’ category of Everest Group’s Life Sciences Sales and Marketing Operations PEAK Assessment.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, today announced that it has been selected as winner of the “Best AI-based Solution for Healthcare” award in the sixth annual AI Breakthrough Awards, a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market today.

IQVIA™ (NYSEIQV) today announced the launch of IQVIA RIM Smart Labeling, a comprehensive labeling solution for the life sciences industry that provides an intelligence-driven approach for more efficient and compliant global label management. Through this unique solution, life sciences companies can consolidate regulatory label planning, tracking and execution systems and workflows into one streamlined process.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, announced a groundbreaking partnership today with (RED), the organization co-founded by Bono and Bobby Shriver to fight AIDS and the injustices that enable pandemics to thrive, to support laboratory system strengthening and save lives.

Global research and development activity in oncology remained at historically high levels in 2022, up 22% from 2018, and the global number of patients treated with approved medicines increased at an average of 5% annually over the same period, according to a new report from the IQVIA Institute for Human Data Science on Global Oncology Trends 2023. Over the last five years, a total of 115 novel active substances in oncology have launched globally; simultaneously, clinical development productivity — defined as trial complexity factored by duration and divided by the probability of success — in oncology has been trending down. Diversity and inclusion of Black/African American and Hispanic patient populations in oncology clinical trials lag behind trials in all other top therapeutic areas.

IQVIA Holdings Inc. (NYSEIQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $1,000,000,000 through an offering of senior secured notes due 2028 and senior notes due 2030 (collectively, the “Notes”).

IQVIA (NYSEIQV) today announced that Sheetal Telang, vice president of Therapeutic Strategy, has been honored with the 2023 Rising Star award by the Healthcare Businesswoman's Association (HBA).

The U.S. market for medicines grew by 5% in 2022, reaching a total value of $429Bn on a net price basis. This was driven by a range of factors, including an increase in health services utilization, which is now back to pre-pandemic levels, and the entry of new medicines into the market. Balancing these drivers of growth, was a lack of net price increases for branded drugs and patient out-of-pocket costs per retail prescription remaining under $10. This is according to a new report from the IQVIATM Institute for Human Data Science, The Use of Medicines in the U.S. 2023: Usage and Spending Trends and Outlook to 2027.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the company has been recognized as a Leader in Customer Experience Platforms (CXP) by Everest Group for its Orchestrated Customer Engagement (OCE) platform.

In 2022, global clinical trial activity remained resilient even as the COVID-19 pandemic stretched through the year, with a 1% decline in non-COVID trial activity compared to 2021. COVID-19 trials as a percentage of total trial activity dropped from 10% to 6% of the 5,756 total trials run in 2022. Non-COVID trial activity increased by 8% between 2019 and 2022, suggesting a restoration to pre-pandemic growth rates, according to a new report, Global Trends in R&D 2023: Activity, Productivity and Enablers, released by the IQVIA™ Institute for Human Data Science. The report also found that clinical development productivity – a composite metric of success rates, clinical trial complexity and trial duration – increased dramatically in 2022, reversing a 10-year downward trend.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m. ET.

IQVIA (NYSEIQV) has published its 2022 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to FORTUNE magazine’s “World’s Most Admired Companies” list for the sixth consecutive year.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the first life sciences industry collaboration with Alibaba Cloud in China. IQVIA and Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, will be providing solutions hosted in Mainland China leveraging Salesforce on Alibaba Cloud. This will enable customers with a path to begin using or extending their investments on the best-in-class platform for engaging with their customers.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV) will announce its fourth-quarter and full-year 2022 financial results before the market opens on Friday, February 10, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.

The total spending and global demand for medicines will increase over the next five years to approximately $1.9 trillion by 2027, according to a new report titled Global Use of Medicines 2023 – Outlook through 2027 from the IQVIA Institute for Human Data Science.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a long-term collaboration with Clalit, the largest health services organization in Israel, to launch the first Prime Site in the country.

Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory.

IQVIA (NYSEIQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced new evidence that decentralized clinical trials (DCT) deliver measurable benefits for patients, sites and sponsors.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV), announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Baird 2022 Global Healthcare Conference in New York City on Wednesday, September 14, 2022 at 2:35 p.m. ET.

IQVIA (NYSEIQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced it has been named the 2022 Marketplace Healthcare and Life Sciences Partner of the Year by Snowflake, the Data Cloud company.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced the company has been named a Leader in the IDC MarketScape: Worldwide Life Science Sales and Marketing IT Outsourcing Services 2022 Vendor Assessment (doc #US41808017, March 2022). The report noted IQVIA’s deep life sciences domain expertise, global skilled workforce, and breadth of innovative technology and services.

IQVIA (NYSEIQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company’s Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA.

Global research and development in oncology continues to surge with historically high levels of trial starts in 2021, up 56% from 2016. Also, a record 30 novel active substances launched globally last year, according to a new report from the IQVIA Institute for Human Data Science on Global Oncology Trends 2022. While disruptions in cancer care are easing, more new patients were presenting to community oncologists with metastatic disease in several tumors during 2020 and 2021 due to delays in diagnosis and screenings.

Spending on medicines in the United States, at estimated net manufacturer prices, reached $407 billion in 2021, up 12% over 2020, as COVID-19 vaccines and therapeutics became widely available and added $29 billion in related spending. That’s according to a new U.S. Medicines Trends 2022 Report, released today by the IQVIA Institute for Human Data Science. In the same year, the non-COVID medicines market grew more slowly, at 5%, from the growing impact of biosimilars, which increased significantly, offsetting increased use of branded medicines.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that the European Medicines Agency (EMA) has awarded a contract to Erasmus University Medical Center Rotterdam to provide analytics services to the DARWIN EU® Coordination Centre which IQVIA was selected to support. IQVIA will also work alongside the University of Oxford, Synapse, The Hyve, and Odysseus Data Services.

IQVIA™ (NYSEIQV) today announced the launch of OCE+, the first of several new advancements to its leading life science customer engagement platform. OCE+ adds IQVIA’s Next Best recommendation engine – a daily workflow tool providing AI-driven recommendations for engaging healthcare professionals (HCP) – to its Orchestrated Customer Engagement (OCE) platform, providing enhanced HCP experiences, improved productivity, and increased ROI.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry was named the top CRO in Overall Reputation by clinical trial sites around the world in the 2021 WCG CenterWatch Global Site Relationship Benchmark Survey Report.

IQVIA (NYSEIQV) today published its 2021 Environmental, Social, and Governance (ESG) Report. The annual report highlights the significant efforts the company has made in advancing healthcare globally, increasing the diversity and engagement of its workforce, and reducing its global environmental footprint.

Biopharmaceutical R&D continued at a record-breaking pace in 2021 despite the COVID-19 pandemic, according to a new report, “Global Trends in R&D – Overview Through 2021,” by the IQVIA Institute for Human Data Science. The data show 5,500 new planned clinical trial starts occurred last year, a 14% increase over 2020.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV) will announce its fourth-quarter and full-year 2021 financial results before the market opens on Tuesday, February 15, 2022. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.

IQVIA (NYSEIQV) today announced the appointment of Sheila A. Stamps to its board of directors, effective today. Ms. Stamps brings more than four decades of strategic, governance and operational management experience. During her extensive career she held senior executive leadership positions in both public and private sector organizations, most recently as a senior investment advisor to the Comptroller of the State of New York for the NYS Common Retirement Fund and as Commissioner on the board of the New York State Insurance Fund, the state’s largest provider of worker’s compensation insurance. Prior to this, she was a Managing Director at Bank of America and Managing Director and Executive Management Committee Member at Bank One London (now, JPMorgan Chase).

IQVIA (NYSEIQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, announced the appointment of Leslie Wims Morris to its board of directors, effective today.

Global spending on medicines — based on invoice price levels — is expected to grow at 3-6% CAGR through 2026 to reach about $1.8 trillion by 2026, including spending on COVID-19 vaccines and novel therapeutics, according to a new report, The Global Spending and Usage of Medicines, released by the IQVIA™ Institute for Human Data Science.

IQVIA (NYSEIQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, is launching new Research Nursing and Phlebotomy services. These new services offer patients participating in clinical trials access to a global network of high-quality, credentialed professionals that provide compassionate protocol-required care within their own homes.

IQVIA (NYSEIQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, was judged a Leader by International Data Corporation (IDC) in its 2021 MarketScapeTM focused on the Worldwide Life Science Sales and Marketing Business Process Outsourcing (BPO) Pharma space. IDC reached its conclusion based on in-depth and rigorous analysis utilized in its MarketScape research.

IQVIA (NYSEIQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced the launch of Grants and Funding Management, new module within the Orchestrated Customer Engagement (OCE) solutions portfolio. From grant submission to payment processing and closeout, IQVIA Grants and Funding Management provides life sciences companies with a solution to efficiently manage and oversee their global strategic giving programs.

IQVIA (NYSEIQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced the launch of Grants and Funding Management, new module within the Orchestrated Customer Engagement (OCE) solutions portfolio. From grant submission to payment processing and closeout, IQVIA Grants and Funding Management provides life sciences companies with a solution to efficiently manage and oversee their global strategic giving programs.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV) will announce its third-quarter 2021 financial results before the market opens on Thursday, October 21, 2021. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.

IQVIA™, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced the opening of a state-of-the-art, 160,000-square-foot lab facility for its Q2 Solutions subsidiary. These custom-designed laboratory spaces will be known as Q2 Solutions Innovation Laboratories and are located on the new IQVIA Innovation Park Campus in the heart of the dynamic Research Triangle Park in North Carolina. Through a collaboration with the North Carolina Department of Commerce and the Economic Development Partnership of North Carolina, IQVIA anticipates that this new facility will create up to 750 new jobs in North Carolina over the next 10 years.